DTI Lifts Trade Ban on AEROGIN and RELX, FLARE and Others Still Need PS Certification

Nov.26.2024

DTI Lifts Trade Ban on AEROGIN and RELX, FLARE and Others Still Need PS Certification

The Philippine Department of Trade and Industry (DTI) has lifted the trade ban on AEROGIN and RELX, while products from brands like FLARE, NIXX, and VAPENGIN still require Philippine Standards (PS) certification before they can be sold.

The Department of Trade and Industry (DTI) has officially lifted the suspension on the sale of vape products produced by AEROGIN and RELX.

At the same time, the DTI has removed the Preliminary Order/Preventive Measure Order against FLARE, NIXX, and VAPENGIN products. However, the sale of these products will remain prohibited until they secure the necessary Philippine Standard (PS) certification.

DTI emphasizes its commitment to ensuring the safety and quality of vape products in the Philippine market through strict enforcement of regulatory standards. Under Republic Act No. 11900 (RA11900), also known as the "Vaporized Nicotine and Non-Nicotine Products Regulation Act," and related regulations, the Office for the Special Mandate on Vaporized Nicotine and Non-Nicotine Products (OSMV) has the authority to take immediate action, including the recall, restriction, or confiscation of non-compliant vape products, devices, or novel tobacco products, following due process.

References:

[1] DTI lifts suspension of vape brands

Also Read:

[1] DTI suspends sales of 11 e-cigarette brands in the Philippines

[2] DTI Initiates Legal Action Against Four E-Cigarette Brands Including RELX, Flare

[3] DTI Suspends Sales of 5 E-cigarette Brands in Philippines, Including LOST MARY, Chillax, SHFTDr.Freeze, Aerogin, Don Bars, Black Elite

[4] Philippine Customs Seizes $33.8k Worth of E-Cigarettes in Warehouses

#Legislation #Asia #Open system e-cigarettes #Philippines

China Tobacco Regulation Shift：Policy Updates and Market Impact

China Tobacco Regulation Shift：Policy Updates and Market Impact

Inside Nicotine-Pouch M&A Through Imperial's Yoik Deal: Latham, KPMG, PwC, Goldman Sachs and Morgan Stanley Form the Adviser Lineup

Inside Nicotine-Pouch M&A Through Imperial's Yoik Deal: Latham, KPMG, PwC, Goldman Sachs and Morgan Stanley Form the Adviser Lineup

Imperial Brands' acquisition of Swedish Helwit owner Yoik Group AB has highlighted the professional-services firms supporting cross-border oral nicotine M&A. Latham & Watkins and KPMG advised Imperial, while PwC and TM & Partners advised Yoik. KPMG also appeared on Imperial's acquisition of Black Buffalo earlier in 2026, while PwC played an extensive role in KT&G's acquisition of Swedish nicotine-pouch company Another Snus Factory. Imperial's public disclosures put the global modern oral nicotine delivery market at approximately £8.8 billion in retail sales and 23.5 billion pouches in 2024

UK HMRC Issues One-Month Countdown Warning, Urges Vape Businesses to Prepare for New Tax Rules

UK HMRC Issues One-Month Countdown Warning, Urges Vape Businesses to Prepare for New Tax Rules

The UK’s Vaping Products Duty and Vaping Duty Stamps Scheme will take effect on October 1, 2026. All vaping liquids manufactured in or imported into the UK will face a flat excise duty of £2.20 per 10ml, whether or not they contain nicotine. Newly manufactured or imported products released onto the UK market from October 1 will require a valid duty stamp, while eligible existing unstamped inventory can continue to be sold through March 31, 2027. From April 1, 2027, all vaping products outside duty suspension must carry a valid stamp.

How Large Is France’s Off-Channel Tobacco Market? Logista Says It Has Become Structural, While the Official Estimate Is 17.7% and Some Industry Studies Put It Above 50%

How Large Is France’s Off-Channel Tobacco Market? Logista Says It Has Become Structural, While the Official Estimate Is 17.7% and Some Industry Studies Put It Above 50%

Logista France says tobacco consumption outside France’s official tobacconist network has become a large and structural market phenomenon, but official and industry estimates differ sharply. France’s TAFE study estimates that 17.7% of tobacco consumption escaped domestic taxation in 2023, with most of that volume attributed to cross-border purchasing rather than street sales. Some industry studies use broader off-channel definitions and put the figure above 50%. Meanwhile, French Customs seized 547.94 tonnes of tobacco in 2025, up 12%, showing continued pressure from illicit trade.

Ireland Raises Nicotine Product Taxes Again as Cigarettes Gain €1 and Vape Duty Is Set to Jump 40%

Ireland Raises Nicotine Product Taxes Again as Cigarettes Gain €1 and Vape Duty Is Set to Jump 40%

Ireland has increased tobacco excise under Budget 2027 and announced a further rise in its E-liquid Products Tax. From Oct. 7, the tax burden on a pack of 20 cigarettes in the most popular price category increased by €1, with pro-rata increases on other tobacco products. The government plans to raise EPT from €0.50 to €0.70 per millilitre from Jan. 1, 2027, a 40% increase applying to both nicotine-containing and nicotine-free e-liquids. The tobacco duty increase is expected to raise about €63.1 million in a full year.

U.S. Ninth Circuit Upholds FDA Denial of MH Global’s Flavored Vape PMTA Applications

U.S. Ninth Circuit Upholds FDA Denial of MH Global’s Flavored Vape PMTA Applications

The U.S. Court of Appeals for the Ninth Circuit upheld the FDA’s denial of MH Global LLC’s applications to market flavored electronic nicotine delivery systems (ENDS). The court ruled that FDA’s comparative-efficacy framework, which requires applicants to show that flavored products provide greater cessation or switching benefits than tobacco-flavored alternatives, is consistent with the Tobacco Control Act’s “appropriate for the protection of the public health” standard. The court also found that FDA was not required to establish the framework through notice-and-comment rulemaking.

Special Report | Can Nicotine Be Replaced? 6-MN Is Already on the Market While Key Human Evidence Is Still Missing

Special Report | Can Nicotine Be Replaced? 6-MN Is Already on the Market While Key Human Evidence Is Still Missing

Nicotine analogues such as 6-methylnicotine are already appearing in e-cigarettes and oral pouches, even as key human evidence remains limited. A new Nixodine-S study adds nonclinical data showing differences from nicotine in cytotoxicity and receptor activity, while independent studies point to a more complex toxicological picture. With supply-chain activity growing and FDA seeking clearer authority over nicotine analogues, the industry now faces a larger question: what evidence is needed before these substances can credibly replace nicotine?

Related Topics

News Regulation

Related Read

Inside Nicotine-Pouch M&A Through Imperial's Yoik Deal: Latham, KPMG, PwC, Goldman Sachs and Morgan Stanley Form the Adviser Lineup

Inside Nicotine-Pouch M&A Through Imperial's Yoik Deal: Latham, KPMG, PwC, Goldman Sachs and Morgan Stanley Form the Adviser Lineup

UK HMRC Issues One-Month Countdown Warning, Urges Vape Businesses to Prepare for New Tax Rules

UK HMRC Issues One-Month Countdown Warning, Urges Vape Businesses to Prepare for New Tax Rules

How Large Is France’s Off-Channel Tobacco Market? Logista Says It Has Become Structural, While the Official Estimate Is 17.7% and Some Industry Studies Put It Above 50%

How Large Is France’s Off-Channel Tobacco Market? Logista Says It Has Become Structural, While the Official Estimate Is 17.7% and Some Industry Studies Put It Above 50%

Ireland Raises Nicotine Product Taxes Again as Cigarettes Gain €1 and Vape Duty Is Set to Jump 40%

Ireland Raises Nicotine Product Taxes Again as Cigarettes Gain €1 and Vape Duty Is Set to Jump 40%

U.S. Ninth Circuit Upholds FDA Denial of MH Global’s Flavored Vape PMTA Applications

U.S. Ninth Circuit Upholds FDA Denial of MH Global’s Flavored Vape PMTA Applications

Special Report | Can Nicotine Be Replaced? 6-MN Is Already on the Market While Key Human Evidence Is Still Missing

Special Report | Can Nicotine Be Replaced? 6-MN Is Already on the Market While Key Human Evidence Is Still Missing